Hospital de la Santa Creu i Sant Pau, Servei de Bioquímica - IIB Sant Pau, Barcelona, Spain; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain; Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Spain.
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain; Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau- IIB Sant Pau, Barcelona, Spain.
Atherosclerosis. 2019 Apr;283:52-60. doi: 10.1016/j.atherosclerosis.2019.01.036. Epub 2019 Feb 11.
Primary hypobetalipoproteinemia is generally considered a heterogenic group of monogenic, inherited lipoprotein disorders characterized by low concentrations of LDL cholesterol and apolipoprotein B in plasma. Lipoprotein disorders include abetalipoproteinemia, familial hypobetalipoproteinemia, chylomicron retention disease, and familial combined hypolipidemia. Our aim was to review and analyze the results of the molecular analysis of hypolipidemic patients studied in our laboratory over the last 15 years.
The study included 44 patients with clinical and biochemical data. Genomic studies were performed and genetic variants were characterized by bioinformatics analysis. A weighted LDL cholesterol gene score was calculated to evaluate common variants associated with impaired lipid concentrations and their distribution among patients.
Twenty-three patients were genetically confirmed as affected by primary hypobetalipoproteinemia. In this group of patients, the most prevalent mutated genes were APOB (in 17 patients, with eight novel mutations identified), SAR1B (in 3 patients, with one novel mutation identified), ANGPTL3 (in 2 patients), and MTTP (in 1 patient). The other 21 patients could not be genetically diagnosed with hypobetalipoproteinemia despite presenting suggestive clinical and biochemical features. In these patients, two APOB genetic variants associated with lower LDL cholesterol were more frequent than in controls. Moreover, the LDL cholesterol gene score, calculated with 11 SNPs, was significantly lower in mutation-negative patients.
Around half of the patients could be genetically diagnosed. The results suggest that, in at least some of the patients without an identified mutation, primary hypobetalipoproteinemia may have a polygenic origin.
原发性低β脂蛋白血症通常被认为是一组异质性的单基因遗传性脂蛋白紊乱,其特征为血浆中 LDL 胆固醇和载脂蛋白 B 浓度降低。脂蛋白紊乱包括无β脂蛋白血症、家族性低β脂蛋白血症、乳糜微粒滞留病和家族性混合型高脂血症。我们的目的是回顾和分析过去 15 年在我们实验室研究的降脂患者的分子分析结果。
该研究纳入了 44 名具有临床和生化数据的患者。进行了基因组研究,并通过生物信息学分析对遗传变异进行了特征描述。计算了加权 LDL 胆固醇基因评分,以评估与脂质浓度受损相关的常见变异及其在患者中的分布。
23 名患者经基因证实患有原发性低β脂蛋白血症。在这组患者中,最常见的突变基因是 APOB(17 例,其中 8 例为新发现的突变)、SAR1B(3 例,1 例新发现的突变)、ANGPTL3(2 例)和 MTTP(1 例)。其他 21 名患者尽管具有提示性的临床和生化特征,但无法通过基因诊断出低β脂蛋白血症。在这些患者中,两种与 LDL 胆固醇降低相关的 APOB 遗传变异比对照组更为常见。此外,用 11 个 SNP 计算的 LDL 胆固醇基因评分在突变阴性患者中显著降低。
约一半的患者可以通过基因诊断。结果表明,在至少一些未发现突变的患者中,原发性低β脂蛋白血症可能具有多基因起源。